Malignant Gliomas Biorepository Core

与所涉疾病相关的可靠模型系统是实现发展的重要资产 安全有效的治疗方法它与胶质母细胞瘤特别相关，因为这种肿瘤由以下组成： 患者中异质性多种类型的肿瘤细胞。最近的研究表明， 球状体培养使我们能够保持亲本的原始表型和遗传特征， 肿瘤的核心C将利用其目前的服务，收集更多的胶质母细胞瘤球状体（GS）， 受影响的患者，并揭示这些GS的表型和基因型特征， 与目标2中详述的每个项目相关。具体地说，我们将从外科手术中建立球状体培养物， 标本，并进行体内致瘤性测定，以确定我们的样品是否能够重现 患者的肿瘤组织病理学检查。我们还计划为所有人持续提供这些服务。 五年的补助金，因为特点GS转移到每个项目可能需要重新定性。 因此，该核心将为所有4个项目提供必要的服务。该核心作为核心的意义 生物储存库将消除项目之间的差异，确保所有项目使用相同的GS， 提出的实验。

A reliable model system that is relevant to the disease in question is a critical asset to achieve development of safe and effective therapeutics. It is in particular relevant for glioblastoma, since this tumor is composed of heterogeneous multiple types of tumor cells in patients. Recent studies identified that application of the spheroid cultures enables us to maintain the original phenotypic and genetic characteristics of the parental tumors. Core C will utilize its current services to collect additional glioblastoma spheroids (GSs) from affected patients and uncover the phenotypic and genotypic characteristics of these GSs are particularly relevant to each project as detailed in aim 2. Specifically, we will establish spheroid cultures from surgical specimens and perform in vivo tumorigenicity assay to determine if our samples are able to recapitulate patients' tumors histopathologically. We also would plan to provide these services on an ongoing basis for all five years of the grant since characterized GSs transferred to each project may require re-characterization. As such, this Core will provide services essential to all 4 projects. Significance of this Core as a central biorepository will eliminate variability amongst the projects, ensuring that all projects utilize the same GSs for the proposed experiments.